Skip to main content

Table 2 Variables related to renal replacement therapy during the ICU stay

From: Daily urinary urea excretion to guide intermittent hemodialysis weaning in critically ill patients

Variables

All patients (n = 67)

Unweaned (n = 30)

Weaned (n = 37)

P value

Duration of RRT, days

11 (7–15)

10 (7–15)

11 (8–15)

0.90

Patients treated with CRRT, n (%)

20 (30)

7 (23)

13 (35)

0.05

Duration of CRRT, days

5 (2–7)

3 (3–6.5)

5 (2–7)

0.90

Patients treated with hemofiltrationa, n (%)

9 (13)

3 (10)

6 (16)

0.46

Patients treated with hemodiafiltrationb, n (%)

11 (16)

4 (13)

7 (19)

0.54

Prescribed total effluent flow of CRRTc, ml/kg/day

45.7 (44.4–47.0)

42.8 (42.0–43.6)

46.5 (45.3–48.5)

0.23

Blood flow of CRRT, ml/minute

200 (200–200)

200 (200–200)

200 (200–200)

0.34

IHD sessions during ICU stay, n

7 (5–10)

7 (5–9)

7 (5–10)

0.47

Duration of IHD session, h

4.1 (3.7–4.6)

4.0 (3.8–4.5)

4.2 (3.5–4.6)

0.88

IHD sessions per week, n

5.5 (4.4–6.2)

5.0 (4.4–6.1)

5.8 (4.4–6.4)

0.29

Blood flow of IHD, ml/minute

214 (200–240)

233 (208–250)

209 (200–217)

0.01

Dialysate flow, ml/minute

540 (500–586)

530 (500–571)

545 (500–596)

0.52

K∙t/V/IHD sessiond

0.91 (0.73–1.09)

0.82 (0.71–1.08)

0.95 (0.76–1.09)

0.83

Net ultrafiltration, L/h

0.25 (0.18–0.38)

0.24 (0.18–0.38)

0.27 (0.18–0.38)

0.66

Percentage of IHD sessions with hypotensione

16.6 (0.00–25.0)

16.6 (0.00–24.0)

15.5 (0.00–27.7)

0.60

  1. RRT renal replacement therapy, CRRT continuous renal replacement therapy, IHD intermittent hemodialysis
  2. Data are presented as median (interquartile range) or count (%)
  3. aAll hemofiltration was delivered with predilution mode
  4. bAll hemodiafiltration was delivered with postdilution mode and a ratio of dialysate to postdilution effluent equal to 1:1
  5. cFor hemodiafiltration, the total effluent was the sum of the dialysate and the postdilution effluent
  6. dK∙t/V was measured with ionic dialysance
  7. eHypotension requiring fluid challenge or increase of vasoactive drug